DXEK has direct effect on corneal hysteresis & biomechanics

Article

Descemetorhexis with endokeratoplasty (DXEK) has a direct effect on corneal hysteresis and the biomechanical properties of the human cornea.

Descemetorhexis with endokeratoplasty (DXEK) has a direct effect on corneal hysteresis and the biomechanical properties of the human cornea, according to Thomas John and colleagues from Loyola University, Chicago, USA.

In this first report on corneal hysteresis and corneal resistance factor following sutureless corneal graft, i.e. DXEK, surgery, 12 eyes of 12 DXEK patients (group1) and 88 eyes of 44 age-matched normal subjects (group 2) were studied. All DXEK subjects were operated on by a single surgeon and the donor corneal disks were surgeon-cut, using the microkeratome and artificial anterior chamber (Moria). None of the eyes had anterior corneal slits to the host-donor interface and all subjects underwent corneal biomechanical evaluation with the Reichert ocular response analyser (ORA).

It was discovered that ORA corneal hysteresis measurements were significantly lower in the DXEK patients (6.94±1.65) than in normal subjects (10.51±1.22). DXEK also had a direct effect on the biomechanical properties of the human cornea, as evidenced by the corneal resistance factor measurements (group1: 8.60±2.10 versus group 2: 9.86±1.23).

The researchers stated that this was the first report of corneal hysteresis and corneal resistance factor following DXEK surgery.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.